Search clinical trials for: IVA337

Total 35 results

Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
Inventiva Pharma

Completed

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (FASST)

Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis

United Kingdom, France, Spain, Switzerland, Italy, Slovenia, Netherlands, Germany, Bulgaria, Poland
Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
Novartis Pharmaceuticals

Completed

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Germany, Hungary, Belgium, Poland, Spain, Netherlands
Inventiva Pharma

Completed

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
ImmVirx Pty Ltd
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Gastric Cancer | Colorectal Cancer | Ovarian Cancer

Australia
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
Novartis Pharmaceuticals

Withdrawn

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (GLOW8)

Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Novartis

Completed

Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Denmark
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

Asthma
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (GLOW7)

Chronic Obstructive Pulmonary Disease (COPD)

China, Philippines, Korea, Republic of, India
Novartis Pharmaceuticals

Completed

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

Renal Impairment

Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Novartis Pharmaceuticals

Completed

NVA237 BID Versus Placebo Twelve-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

NVA237 Versus Placebo 12-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (FAST)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (GLOW5)

Chronic Obstructive Pulmonary Disease

Germany, India, South Africa, Croatia, Estonia, Poland, Lithuania, Guatemala, Czech Republic, France, Philippines, Korea, Republic of, Taiwan, Canada, Latvia
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis Pharmaceuticals

Completed

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (SYNERGY)

Chronic Obstructive Pulmonary Disease: COPD

Switzerland
Novartis

Completed

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Germany
Novartis Pharmaceuticals

Completed

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Asthma

Germany, United States, Belgium, Latvia, Lithuania, Japan
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Pharmaceuticals

Completed

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (GLOW3)

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom, Italy, United States, Romania
Novartis Pharmaceuticals

Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Asthma

Spain, Hungary, United Kingdom, South Africa, Colombia, Guatemala, Bulgaria, Poland
Novartis Pharmaceuticals

Completed

Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (GLOW4)

Chronic Obstructive Pulmonary Disease

Japan
Novartis Pharmaceuticals

Withdrawn

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Pulmonary Disease, Chronic Obstructive
Affect Therapeutics, Inc.

Completed

Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder

Methamphetamine Abuse

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

Chronic Obstructive Pulmonary Disease

Belgium, France, Japan
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Germany, Poland, Romania, Hungary, Sweden, Russian Federation, Bulgaria, Finland, Israel, Belgium
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more

Search clinical trials for: IVA337

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations